Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | TACR3 | P29371 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PTGFR | P43088 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945399 | 0.90 | PDE10A (0.68) | DHODHTSHRPDE10ATACR3 | |
| SCHEMBL5945348 | 0.88 | DHODH (0.63) | DHODHTSHRPDE10ATACR3MAPT | |
| Hydrochloric Acid SCHEMBL6848801 | 0.87 | DHODH (0.61) | DHODHTSHRPDE10ATACR3MAPT | |
| SCHEMBL4463839 | 0.83 | PDE10A (0.77) | DHODHTSHRPDE10ATACR3ALDH1A1 | |
| SCHEMBL7451940 | 0.79 | DHODH (0.56) | DHODHTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6451847 | 0.79 | ALDH1A1 (0.55) | TACR3MAPTALDH1A1SMN1; SMN2PTGFR | |
| SCHEMBL4471465 | 0.78 | TACR3 (0.82) | TSHRTACR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL4471472 | 0.78 | TACR3 (0.82) | TSHRTACR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL13957888 | 0.77 | PTGFR (0.63) | DHODHPTGFR | |
| SCHEMBL2373290 | 0.77 | DHODH (0.59) | DHODHTSHRPDE10AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20060160846-A1 | Quinoline derivatives | SMITHKLINE BEECHAM FARMAEUTICI S.P.A. | 2006-07-20 | — | — | US | disclosed |
| US-20050096316-A1 | Neutokinin (NK3) receptor antagonists; pulmonary disorders, nervous system disorders and neurodegenerative disorders | FARINA CARLO (IT) | 2005-05-05 | — | — | US | disclosed |
| EP-0940391-B1 | Quinoline derivatives as tachykinin NK3 receptor antagonists | GLAXOSMITHKLINE SPA (IT) | 2004-08-18 | — | — | EP | disclosed |
| US-6743804-B2 | A QUINOLINE DERIVATIVES, FOR TREATMENT OF CERTAIN CONDITIONS BY OVERSTIMULATION OF THE THACHYKININ RECEPTORS, DISORDERS OF CENTRAL NERVOUS SYSTEM, SCHIZOPHRENIA; NEURODEGENERATIVE DISORDERS ALZHEIMER DISEASE AND DOWN'S SYNDROME | SMITHKLINE BEECHAM S P.A. (IT) | 2004-06-01 | — | — | US | disclosed |
| US-20030236281-A1 | Quinoline derivatives(2) | FARINA CARLO (IT) | 2003-12-25 | — | — | US | disclosed |
| US-20030195204-A1 | Quinoline derivatives as NK3 antagonists | SMITHKLINE BEECHAM S.P.A. | 2003-10-16 | — | — | US | disclosed |
| US-6608083-B1 | Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease, | SMITHKLINE BEECHAM FARMACEUTICI S.P.A (IT) | 2003-08-19 | — | — | US | disclosed |
| EP-0804419-B1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMA (IT) | 2003-08-06 | — | — | EP | disclosed |
| EP-0940391-A2 | Quinoline derivatives as tachykinin NK3 receptor antagonists | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1999-09-08 | — | — | EP | disclosed |
| EP-0874827-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | Smithkline Becham S.P.A. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5811553-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, PULMONARY DISORDERS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1998-09-22 | — | — | US | disclosed |
| EP-0804419-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997019927-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195204-A1 | Quinoline derivatives as NK3 antagonists | KCNK3, KCND3, KCNN3 | DHODH 1916/4885TSHR 2427/4885PDE10A 1648/4885 |
| US-20060160846-A1 | Quinoline derivatives | CHRNA3, CHRNB3, KCNQ3 | DHODH 1945/4885TSHR 1185/4885PDE10A 3085/4885 |
| US-20030236281-A1 | Quinoline derivatives(2) | KCNQ3, CHRNA3, KCNK3 | DHODH 1855/4885TSHR 931/4885PDE10A 3540/4885 |
| US-20050096316-A1 | Neutokinin (NK3) receptor antagonists; pulmonary disorders, nervous system disorders and neurodegenerative disorders | TACR3, CHRNB3, CHRNA3 | DHODH 4490/4885TSHR 578/4885PDE10A 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.